Across TCGA pan-cancer cohorts, GSR Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GSR data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GSR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GSR expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
HNSC, UCEC, and PRAD are the cancer types where GSR Mutation most reproducibly stratifies survival.